Celyad

Kempen is pleased to announce that it acted as adviser to Celyad in its USD 54.4m global offering 

• The transaction comprised 2,070,000 new shares in the form of:
  - American Depositary Shares (ADSs) at a price of USD 26.28 per ADS
  - Ordinary shares at a price of €22.29 per ordinary share 
  - Each ADS represents the right to receive one ordinary share
• Gross proceeds amount to USD 47.3m/€40.1m and will be used to, amongst others, advance the development of CYAD-01 through Phase 1 and potentially Phase 2 clinical development as a treatment for up to seven refractory cancers and to advance additional CAR T-cell therapy drug product candidates for the treatment of additional blood cancers and solid tumors
• While initially allowing for two days of bookbuilding, the orderbook closed ahead of schedule on the back of strong European and US momentum
• The orderbook was well-subscribed, c.70% of the demand was generated by Life Sciences specialist investors. The top 10 orders were allocated c.65% of the deal
• This transaction marks Kempen’s fourth Life Sciences transaction this year and the third US Life Sciences ECM transaction in which Kempen acted as adviser over the last 12 months

Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized CAR T-cell based therapies. Celyad utilizes its expertise in cell engineering to target cancer. Celyad’s Natural Killer Receptor based T-cell platform has the potential to treat a broad range of solid and hematologic tumors. Its lead oncology candidate, CYAD-01, has been evaluated in a single dose escalation Phase 1 clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers including five solid tumors (colorectal, ovarian, bladder, triple-negative breast and pancreatic cancers) and two hematological tumors (acute myeloid leukemia and multiple myeloma). Celyad was founded in 2007 and is listed on the Euronext Brussels and Euronext Paris exchanges since 2013 and on NASDAQ since 2015.